Company Revenue

The company grew in the low-single-digits in the first quarter of 2024 as supply and commercial struggles in the U.S....

The company's orthopedic sales grew more than 22% in 1Q24 as volume and staffing improve in the pediatric market....

The company's orthopedic sales grew in the mid-single-digits during 1Q24 as the company reduced headcount to control costs....

The company's MACI sales grew nearly 18% in the first quarter of 2024 with the launch of MACI Arthro expected...

The company grew more than 17% in the first quarter of 2024 despite a difficult comparison and one less selling...

The company grew more than 20% in the first quarter of 2024 but lowered its full-year guidance due to increased...

The company grew 27% in the first quarter of 2024 as it further capitalized on disruption in the spine market....

The company drove strong results for its non-surgical hyaluronic acid pain treatments and surgical bone graft substitutes....

The company grew in the high single digits for the first quarter of 2024, including above-market growth in the United...

The combined company integrated its field organizations during the first quarter and drove low-single-digit pro forma growth....